Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Current Deferred Revenue (2019 - 2025)

Pulmonx (LUNG) has disclosed Current Deferred Revenue for 7 consecutive years, with $100000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue fell 8.26% to $100000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $100000.0, a 8.26% decrease, with the full-year FY2024 number at $100000.0, changed 0.0% from a year prior.
  • Current Deferred Revenue was $100000.0 for Q3 2025 at Pulmonx, up from $78000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $200000.0 in Q4 2021 to a low of $75000.0 in Q1 2021.
  • A 5-year average of $107684.2 and a median of $100000.0 in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 100.0% in 2021, then tumbled 40.0% in 2022.
  • Pulmonx's Current Deferred Revenue stood at $200000.0 in 2021, then crashed by 40.0% to $120000.0 in 2022, then fell by 16.67% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Current Deferred Revenue are $100000.0 (Q3 2025), $78000.0 (Q2 2025), and $100000.0 (Q1 2025).